Liquidia (LQDA) announced that United Therapeutics Corporation, or UTHR, filed a complaint on May 9, in the U.S. District Court for the Middle District of North Carolina against Liquidia alleging infringement of U.S. Patent No. 11,357,782. Additionally, the complaint seeks to enjoin Liquidia from commercializing YUTREPIA, or treprostinil, inhalation powder if approved by the FDA to treat pulmonary arterial hypertension, or PAH, and pulmonary hypertension associated with interstitial lung disease, or PH-ILD. The ‘782 patent, which issued on June 14, 2022. UTHR is currently not seeking any injunction against the FDA to prevent final approval of the New Drug Application for YUTREPIA. As previously announced, the FDA set a Prescription Drug User Fee Act goal date of May 24.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Positive Outlook for Liquidia Technologies Amid Legal Victories and Imminent PDUFA Date for Yutrepia
- Liquidia price target raised to $29 from $27 at Raymond James
- Liquidia Corporation Awaits FDA Decision on YUTREPIA
- Favorable Court Decision and Market Potential Propel Liquidia Technologies’ Buy Rating
- Liquidia reports Q1 EPS (45c) vs. (40c) last year